November 21, 2012 — The article by Bleyer and Welch[1] in the New England Journal of Medicine, which suggests that screening mammography finds many cancers that would not advance to kill patients, is based on false assumptions, according to the American College of Radiology (ACR) and the Society of Breast Imaging (SBI). The thesis depends on their suggestion that the incidence of breast cancer is much higher than would have been expected had screening not been initiated.

The authors suggest that the baseline incidence of breast cancer would have increased by 0.5 percent each year, when in fact the data show that it would likely have increased by twice that amount. The incidence of invasive breast cancer has actually increased by 1 percent per year for decades.[2] In 1940, it was 60/100,000. By 1980, prior to any screening, it had risen to 100/100,000. If there had been no screening, and the rate had continued to increase as it had for 40 years, the incidence in 2008 would have been more than 130/100,000. In fact, due to prevalence screening, where new women who have never been screened enter the screened population each year, and lead time (cancers found earlier due to screening), the incidence of breast cancer without any "overdiagnosis" would have been expected to be even higher than 130/100,000. In reality, it was lower even than that, at 127/100,000.

Therefore, not only is there no evidence of the authors' claimed "overdiagnosis," but it is likely that treatment of ductal carcinoma in situ (DCIS) over the past decades has reduced the incidence of invasive cancers. This is in addition to the observed 30 percent reduction in deaths each year due largely to screening. While the authors observe that screening is associated with a reduction in advanced stage cancers, ACR and SBI claim that they fail to recognize the fact that a reduction in advanced stage disease is not required to have a reduction in deaths from screening.

References:
[1] Bleyer A, Welch HG. Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence. N Engl J Med 367;21:1998-2005.

[2] Garfinkel L, Boring CC, Heath CW Jr. Changing Trends: An Overview of Breast Cancer Incidence and Mortality. Cancer. 1994 Jul 1;74(1 Suppl):222-7).


Related Content

News | FDA

Dec. 8, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, has submitted a 510(k) premarket ...

Time December 08, 2025
arrow
News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
News | Mammography

Nov. 30, 2025 — At RSNA 2025, Siemens Healthineers will introduce new capabilities for its Mammomat B.brilliant ...

Time December 02, 2025
arrow
News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Women's Health

Dec. 1, 2025 — A study of data from seven outpatient facilities in the New York region found that 20-24% of all the ...

Time December 02, 2025
arrow
News | Mammography

Nov. 26, 2025 — GE HealthCare has announced it received FDA Premarket Authorization for Pristina Recon DL, an advanced ...

Time November 29, 2025
arrow
News | Ultrasound Imaging

Nov. 12, 2025 — GE HealthCare and DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., have announced their ...

Time November 20, 2025
arrow
News | Breast Imaging

Nov. 17, 2025 — RadNet, Inc. and its wholly owned subsidiary, DeepHealth have announced results from the largest real ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
Subscribe Now